专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080206190A1 Glycosylated IL-7, Preparation And Uses 有权
标题翻译：糖基化IL-7，制备和用途
公开(公告)号：US20080206190A1
公开(公告)日：2008-08-28
申请号：US11996176
申请日：2006-07-19
申请人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
发明人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
IPC分类号： A61K38/21 , C07K14/00 , C12N15/11 , C12N15/00 , C12N5/06 , A61P37/00 , A61K45/00 , C07K16/18 , C12P21/04 , A61K39/395
CPC分类号： C07K14/5418 , A61K38/00 , Y02A50/385 , Y02A50/393
摘要： The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.
摘要翻译：本发明涉及新的和改进的白细胞介素-7多肽，以及包含其的组合物，其制备和用途。本发明更具体地涉及具有改进性质的高糖基化IL-7多肽及其制备和治疗用途。本发明还公开了具有包含人工产生的糖基化位点的修饰的氨基酸序列以及相应的核酸分子，载体和重组宿主细胞的新型IL-7多肽。本发明还涉及这种多肽，细胞或核酸用于治疗或预防性治疗哺乳动物受试者（包括人类受试者）的用途。

2. 发明申请

US20120016104A1 GLYCOSYLATED IL-7, PREPARATION AND USES 有权
标题翻译： GLYCOSYLATED IL-7，制备和用途
公开(公告)号：US20120016104A1
公开(公告)日：2012-01-19
申请号：US13216331
申请日：2011-08-24
申请人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
发明人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
IPC分类号： C07K14/54
CPC分类号： C07K14/5418 , A61K38/00 , Y02A50/385 , Y02A50/393
摘要： The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.
摘要翻译：本发明涉及新的和改进的白细胞介素-7多肽，以及包含其的组合物，其制备和用途。本发明更具体地涉及具有改进性质的高糖基化IL-7多肽及其制备和治疗用途。本发明还公开了具有包含人工产生的糖基化位点的修饰的氨基酸序列以及相应的核酸分子，载体和重组宿主细胞的新型IL-7多肽。本发明还涉及这种多肽，细胞或核酸用于治疗或预防性治疗哺乳动物受试者（包括人类受试者）的用途。

3. 发明授权

US08034327B2 Hyperglycosylated IL-7, preparation and uses 有权
标题翻译：高糖基化IL-7，制备及用途
公开(公告)号：US08034327B2
公开(公告)日：2011-10-11
申请号：US12711675
申请日：2010-02-24
申请人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
发明人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
IPC分类号： A61K38/20 , C12N5/05
CPC分类号： C07K14/5418 , A61K38/00 , Y02A50/385 , Y02A50/393
摘要： The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.
摘要翻译：本发明涉及新的和改进的白细胞介素-7多肽，以及包含其的组合物，其制备和用途。本发明更具体地涉及具有改进性质的高糖基化IL-7多肽及其制备和治疗用途。本发明还公开了具有包含人工产生的糖基化位点的修饰的氨基酸序列以及相应的核酸分子，载体和重组宿主细胞的新型IL-7多肽。本发明还涉及这种多肽，细胞或核酸用于治疗或预防性治疗哺乳动物受试者（包括人类受试者）的用途。

4. 发明授权

US08153114B2 Hyperglycosylated mammalian IL-7 IgG conjugate composition 有权
标题翻译：高糖基化哺乳动物IL-7 IgG结合物组合物
公开(公告)号：US08153114B2
公开(公告)日：2012-04-10
申请号：US13216331
申请日：2011-08-24
申请人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
发明人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
IPC分类号： A61K38/20 , A61K39/00 , C12P19/00
CPC分类号： C07K14/5418 , A61K38/00 , Y02A50/385 , Y02A50/393
摘要： The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.
摘要翻译：本发明涉及新的和改进的白细胞介素-7多肽，以及包含其的组合物，其制备和用途。本发明更具体地涉及具有改进性质的高糖基化IL-7多肽及其制备和治疗用途。本发明还公开了具有包含人工产生的糖基化位点的修饰的氨基酸序列以及相应的核酸分子，载体和重组宿主细胞的新型IL-7多肽。本发明还涉及这种多肽，细胞或核酸用于治疗或预防性治疗哺乳动物受试者（包括人类受试者）的用途。

5. 发明申请

US20100196312A1 GLYCOSYLATED IL-7, PREPARATION AND USES 有权
标题翻译： GLYCOSYLATED IL-7，制备和用途
公开(公告)号：US20100196312A1
公开(公告)日：2010-08-05
申请号：US12711675
申请日：2010-02-24
申请人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
发明人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
IPC分类号： A61K38/20 , C07K14/54 , A61P37/00
CPC分类号： C07K14/5418 , A61K38/00 , Y02A50/385 , Y02A50/393
摘要： The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.
摘要翻译：本发明涉及新的和改进的白细胞介素-7多肽，以及包含其的组合物，其制备和用途。本发明更具体地涉及具有改进性质的高糖基化IL-7多肽及其制备和治疗用途。本发明还公开了具有包含人工产生的糖基化位点的修饰的氨基酸序列以及相应的核酸分子，载体和重组宿主细胞的新型IL-7多肽。本发明还涉及这种多肽，细胞或核酸用于治疗或预防性治疗哺乳动物受试者（包括人类受试者）的用途。

6. 发明授权

US07708985B2 Glycosylated IL-7, preparation and uses 有权
标题翻译：糖基化IL-7，制备和用途
公开(公告)号：US07708985B2
公开(公告)日：2010-05-04
申请号：US11996176
申请日：2006-07-19
申请人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
发明人： Michel Morre , Brigitte Assouline , Iann Rance , Anne Gregoire , Corinne Breque
IPC分类号： A61K38/20 , C12N5/06
CPC分类号： C07K14/5418 , A61K38/00 , Y02A50/385 , Y02A50/393
摘要： The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.
摘要翻译：本发明涉及新的和改进的白细胞介素-7多肽，以及包含其的组合物，其制备和用途。本发明更具体地涉及具有改进性质的高糖基化IL-7多肽及其制备和治疗用途。本发明还公开了具有包含人工产生的糖基化位点的修饰的氨基酸序列以及相应的核酸分子，载体和重组宿主细胞的新型IL-7多肽。本发明还涉及这种多肽，细胞或核酸用于治疗或预防性治疗哺乳动物受试者（包括人类受试者）的用途。

7. 发明申请

US20050249701A1 Il-7 Drug substance, composition, preparation and uses 有权
标题翻译： II-7药物，成分，制剂及用途
公开(公告)号：US20050249701A1
公开(公告)日：2005-11-10
申请号：US10522883
申请日：2003-08-06
申请人： Michel Morre , Brigitte Assouline , Pierre Cortez , Anne Gregoire
发明人： Michel Morre , Brigitte Assouline , Pierre Cortez , Anne Gregoire
IPC分类号： C12N15/09 , A61K9/08 , A61K38/00 , A61K38/20 , A61K38/21 , A61K39/00 , A61K39/002 , A61K39/04 , A61K39/118 , A61K39/12 , A61K39/145 , A61K39/21 , A61K39/245 , A61K39/25 , A61K39/29 , A61K39/39 , A61K47/12 , A61K47/18 , A61K47/22 , A61K47/26 , A61K47/42 , A61P1/16 , A61P11/00 , A61P31/04 , A61P31/06 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , A61P33/00 , A61P33/02 , A61P35/00 , A61P37/04 , A61P37/06 , C07K14/54 , C07K16/24 , C07K19/00 , C12N1/21 , C12N5/10 , C12N15/24 , C12N15/62 , C12P21/02
CPC分类号： C07K14/5418 , A61K38/00 , C12N2799/022
摘要： The present invention relates, generally, to the fields of immunology and molecular biology. The invention discloses, more particularly, new and improved interleukin-7 drug substances, corresponding specific immunoreactive antibodies, as well as compositions comprising the same, their preparation and uses. The invention also discloses methods to characterize the impurity profile of a r-hIL-7 drug substance used for therapeutic purpose, as well as optimized nucleotide sequences encoding mammalian IL-7, recombinant expression vectors and methods for preparing and purifying said polypeptides. The present invention stems from the unexpected discovery that the long term activity of recombinant IL-7 is mostly expressed by a specific conformer and that other conformers, potential product-related substances, product-related impurities, and process-related impurities, which would normally be included in the specification of the drug substance and/or drug product, although bioactive, should be strictly minimized because they are able to trigger an immune reaction against the desired IL-7 molecule.
摘要翻译：本发明一般涉及免疫学和分子生物学领域。本发明更具体地公开了新的和改进的白细胞介素-7药物物质，相应的特异性免疫反应性抗体，以及包含其的组合物，其制备和用途。本发明还公开了表征用于治疗目的的r-hIL-7药物的杂质分布的方法，以及编码哺乳动物IL-7的优化的核苷酸序列，重组表达载体以及用于制备和纯化所述多肽的方法。本发明源于意想不到的发现，即重组IL-7的长期活性主要由特定构象异构体表达，并且其它构象异构体，潜在的产品相关物质，与产品有关的杂质和与工艺有关的杂质通常被包括在药物物质和/或药物产品的说明书中，尽管生物活性物质应被严格地最小化，因为它们能够引发针对所需IL-7分子的免疫反应。

8. 发明申请

US20140377218A1 HCV IMMUNOTHERAPY 审中-公开
标题翻译： HCV免疫疗法
公开(公告)号：US20140377218A1
公开(公告)日：2014-12-25
申请号：US14236079
申请日：2012-08-02
申请人： Michel Morre , Brigitte Assouline , Therese Croughs , Pierre Demol , Stephanie Beq
发明人： Michel Morre , Brigitte Assouline , Therese Croughs , Pierre Demol , Stephanie Beq
IPC分类号： A61K38/20 , A61K38/21 , A61K45/06
CPC分类号： A61K38/2046 , A61K38/20 , A61K38/21 , A61K45/06
摘要： The invention relates to the use of Interleukin-7 (IL-7), for treating hepatitis C in a patient infected with hepatitis C virus, wherein said patient has been treated or is being treated with an antiviral agent or a combination of antiviral agents that reduces viral load.
摘要翻译：本发明涉及白细胞介素-7（IL-7）用于治疗感染丙型肝炎病毒的患者中的丙型肝炎的用途，其中所述患者已被治疗或正在用抗病毒剂或抗病毒剂的组合治疗，减少病毒载量。

9. 发明授权

US07585947B2 IL-7 drug substance, composition, preparation and uses 有权
标题翻译： IL-7药物，成分，制剂及用途
公开(公告)号：US07585947B2
公开(公告)日：2009-09-08
申请号：US10522883
申请日：2003-08-06
申请人： Michel Christian Morre , Brigitte Assouline , Pierre Cortez , Anne Gregoire
发明人： Michel Christian Morre , Brigitte Assouline , Pierre Cortez , Anne Gregoire
IPC分类号： C07K14/52 , C07K14/00 , C07K1/00 , A61K38/00
CPC分类号： C07K14/5418 , A61K38/00 , C12N2799/022
摘要： The present invention relates, generally, to the fields of immunology and molecular biology. The invention discloses, more particularly, new and improved interleukin-7 drug substances, corresponding specific immunoreactive antibodies, as well as compositions comprising the same, their preparation and uses. The invention also discloses methods to characterize the impurity profile of a r-hIL-7 drug substance used for therapeutic purpose, as well as optimized nucleotide sequences encoding mammalian IL-7, recombinant expression vectors and methods for preparing and purifying said polypeptides. The present invention stems from the unexpected discovery that the long term activity of recombinant IL-7 is mostly expressed by a specific conformer and that other conformers, potential product-related substances, product-related impurities, and process-related impurities, which would normally be included in the specification of the drug substance and/or drug product, although bioactive, should be strictly minimized because they are able to trigger an immune reaction against the desired IL-7 molecule.
摘要翻译：本发明一般涉及免疫学和分子生物学领域。本发明更具体地公开了新的和改进的白细胞介素-7药物物质，相应的特异性免疫反应性抗体，以及包含其的组合物，其制备和用途。本发明还公开了表征用于治疗目的的r-hIL-7药物的杂质分布的方法，以及编码哺乳动物IL-7的优化的核苷酸序列，重组表达载体以及用于制备和纯化所述多肽的方法。本发明源于意想不到的发现，即重组IL-7的长期活性主要由特定构象异构体表达，并且其它构象异构体，潜在的产品相关物质，与产品有关的杂质和与工艺有关的杂质通常被包括在药物物质和/或药物产品的说明书中，尽管生物活性物质应被严格地最小化，因为它们能够引发针对所需IL-7分子的免疫反应。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式